Literature DB >> 12804865

Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin.

K C Bagley1, M T Shata, D Y Onyabe, A L DeVico, T R Fouts, G K Lewis, D M Hone.   

Abstract

Passive antibody studies unequivocally demonstrate that sterilizing immunity against lentiviruses is obtainable through humoral mechanisms. In this regard, DNA vaccines represent an inexpensive alternative to subunit vaccine for mass vaccination programs designed to induce such responses to human immunodeficiency virus type I (HIV-1). At present, however, this vaccine modality has proven relatively ineffective at inducing humoral responses. In this report, we describe the immunogenicity of DNA vaccines that direct the coincident expression of the cholera toxin catalytic domain (CTA1) with that of the human immunodeficiency virus type I gp120 through genes either encoded in individual plasmids or in a single dicistronic plasmid. In BALB/cJ mice, coincident expression of CTA1 in either a separate plasmid or in the dicistronic plasmid in the DNA vaccines induced serum IgG responses to gp120 that were at least 1000-fold greater, and remained elevated longer than, the analogous responses in mice vaccinated with a DNA vaccine that expressed gp120 alone. In addition, mice vaccinated with CTA1 and gp120 produced significantly more gp120-specific IFN-gamma ELISPOTs than mice vaccinated with the gp120 DNA vaccine. Combined, these data show that the adjuvant properties of cholera toxin can be harnessed in DNA vaccine modalities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804865     DOI: 10.1016/s0264-410x(03)00038-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

Review 3.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

4.  Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.

Authors:  Yongjun Sui; George K Lewis; Yichuan Wang; Kurt Berckmueller; Blake Frey; Amiran Dzutsev; Diego Vargas-Inchaustegui; Venkatramanan Mohanram; Thomas Musich; Xiaoying Shen; Anthony DeVico; Timothy Fouts; David Venzon; James Kirk; Robert C Waters; James Talton; Dennis Klinman; John Clements; Georgia D Tomaras; Genoveffa Franchini; Marjorie Robert-Guroff; Giorgio Trinchieri; Robert C Gallo; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

5.  Cholera toxin indirectly activates human monocyte-derived dendritic cells in vitro through the production of soluble factors, including prostaglandin E(2) and nitric oxide.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; George K Lewis
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells.

Authors:  Filippo Veglia; Ester Sciaraffia; Antonella Riccomi; Dora Pinto; Donatella R M Negri; Maria Teresa De Magistris; Silvia Vendetti
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

7.  Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Authors:  Kenneth C Bagley; George K Lewis; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; George K Lewis
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Recombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines.

Authors:  Nyasha Chin'ombe; Vurayai Ruhanya
Journal:  Open Virol J       Date:  2013-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.